(Sharecast News) - American pharmaceutical giant Pfizer expects revenues and profits to slip slightly in 2026, partly as a result of lost revenues from its Covid-19 products.
In an analyst and investor call on Tuesday, the company said it was revising its 2025 revenue guidance to $62.0bn, slightly below the mid-point...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE